Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.
Journal: The New England journal of medicine
Published: May 27, 2026
Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer.
Journal: Cancer chemotherapy and pharmacology
Published: June 27, 2022
Impact of platelet transfusion on outcomes in trauma patients.
Journal: Critical care (London, England)
Published: October 14, 2021
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 08, 2020
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 30, 2019
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
Journal: Cancer
Published: July 30, 2018
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Journal: Investigational new drugs
Published: June 21, 2018
Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
Journal: Breast cancer research and treatment
Published: December 15, 2014
Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer.
Journal: Breast cancer research and treatment
Published: December 08, 2014
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Journal: Investigational new drugs
Published: May 29, 2014
Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Journal: The Journal of surgical research
Published: March 03, 2013
Last Updated: 09/26/2026